Patient must not receive live, attenuated influenza vaccine within  weeks prior to registration or at any time during the study and until  months after the last dose of atezolizumab
Patients must agree not to receive any live, attenuated influenza vaccine (e.g., FluMist) within  days prior to receiving study treatment, during treatment or within  months following the last dose of atezolizumab
